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Abstract
Background: Increasing amounts of evidence indicate that tumor infiltrating lymphocytes (TIL) are correlated with
the prognosis of cancer patients. This study focuses on the association between the densities of tumor infiltrating
cytotoxic T lymphocytes (CTL), activated CTL, regulatory T lymphocytes (Treg) and Th17 lymphocytes, and the
prognosis and clinicopathological features of nasopharyngeal carcinoma (NPC) patients.
Results: Double immunohistochemical staining was performed in 106 biopsy specimens from newly diagnosed
NPC patients. Prognostic values of infiltrating lymphocyte densities were evaluated by Kaplan-Meier analysis and
Cox regression. The density of CD8+ TIL was positively correlated with lymph node metastasis, while the density of
Foxp3
+ TIL was negatively associated with T stage (P < 0.05). For survival evaluation, the density of Foxp3
+ TIL or
Foxp3
+ TIL combined with GrB
+ TIL together was associated with better overall survival (OS) and progression-free
survival (PFS) (P < 0.01) in all patients and in the patients with late-stage diseases (Stages III and IV, P < 0.01).
Meanwhile a low density of CD8
+TIL or high ratio of FOXP3
+TIL to CD8
+TIL was correlated with better PFS in early
stage patients (Stages I and II, P < 0.05). No significant association was found between IL-17
+ TIL and
clinicopathological characteristic or survival of NPC patients.
Conclusions: Our study identifies for the first time the tumor infiltrating Foxp3
+ TIL as an independent favorable
factor in the prognosis of NPC patients, especially for the patients with late-stage diseases.
Background
Nasopharyngeal carcinoma (NPC) is an epithelial neo-
plasm with high incidence in South China and South
Asia, while with low incidence in most countries. There
are three histological classficiation for NPC: Type 1, ker-
atinising squamous-cell carcinoma; Type 2, Non- kerati-
nising squamous-cell carcinoma; Type 3,
Undifferetiation nasopharyngeal carcinoma. Due to the
less symptoms and the difficulty to make clinical exami-
nation of nasopharynx, most patients with this disease
are diagnosed only when the tumour at the advanced
stage. Radiotherapy and concomitant chemoradiotherapy
can improve overall survival and progression-free survi-
val in NPC patients, but the prognosis remains poor in
a significant number of patients with late-stage disease
[1-4].
EBV infection positivity has been identified in most
undifferentiated NPC (95%) by the expression of EBV
latent phase antigens in the tumor cells including LMP1
(40-60%), LMP2, EBNA1 and BARF0. In addition, a
large number of tumor infiltrating lymphocytes (TIL)
are found around the NPC tumor tissues [5-8]. The
majority of the cells in the tumor are reactive and con-
sist predominantly of T cells with variable numbers of
other inflammatory cells [9]. The presence of TIL corre-
lates with an better prognosis in patients with several
types of cancer, and each T lymphocyte subset has a
unique role in the antitumor response [10-14]. Presence
of tumor infiltrating cytotoxic T lymphocytes (CTL) has
been linked to better patient survival in endometrial,
ovarian, pancreatic and colorectal cancers [15-17]. Regu-
latory T cells (Treg) play an essential role in controlling
immune responses to self and non-self antigens. It has
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any medium, provided the original work is properly cited.been reported that the tumor infiltrating Treg cells are
associated with a poorer prognosis in some cancers by
suppressing the proliferation of effector T lymphocyte
(i.e., cytotoxic T lymphocyte (CTL)) to prohibit an ade-
quate tumor-specific immune response, thus enabling
tumor growth [18-23]. In contrast, other researchers
have reported that the tumor infiltrating Treg cells are
either linked to a better prognosis or did not affect
prognosis in some malignancies such as follicular lym-
phoma and squamous cell carcinoma [24-26]. However,
the characteristics and functions of the TIL in NPC are
still poorly understood. With advances in immunological
techniques, adoptive immunotherapy is becoming a pre-
ferred choice with better tolerance. However, the clinical
benefit of EBV-specific CTL-based adoptive immu-
notherapy is only observed in a small number of NPC
patients, maybe due to tumor immune evasion or
immune suppression of the tumor microenvironment
[27,28]. Therefore it is important to understand the
characteristics and functions of TIL and their relation-
ship with tumor clinicopathological features and prog-
nosis, as well as their potential role in immunotherapy
of NPC.
In the present study, we aimed to evaluate the subsets
of TIL including CTL, activated CTL, Treg, and Th17
cells by CD8/Foxp3, GrB/Foxp3 and Foxp3/IL-17 double
IHC staining in 106 paraffin-embedded NPC tumor tis-
sues. We correlated the densities of CD8
+ CTL, GrB
+
activated CTL, Foxp3
+ Treg and IL-17
+ Th17 cells with
the clinical factors and outcomes in all NPC patients as
well as in the patients with different disease stages.
Furthermore, we evaluated the ratio of tumor infiltrating
CD8+ cells to Foxp3
+ cells (the ratio of CD8/Foxp3) and
Foxp3
+ cells together with GrB
+ cells in predicting sur-
vival in all patients as well as in the patients with differ-
ent disease stage.
Results
Patient Characteristics
Among the 106 patients, 84 (79.2%) were male, and the
median age was 49 years (range: 22-73 years). Ninety-
two patients (86.8%) were with histological type III
(undifferentiated) NPC, 13 (12.3%) were with type II
(non-keratinizing) NPC, and only 1 (0.9%) was with type
I (squamous cell carcinoma) disease. Fifty-five (47.4%) of
the tumor tissues were positively stained for EBV LMP1
antigen. Of these 106 patients, only 5 (4.7%) cases were
with distant metastases before treatment, and 88 (83%)
were with lymph node spreading diseases (N1-N3).
Thirty eight (35.9%) patients were in early disease stages
(I and II) while 68 (64.2%) were in late disease stages
(III and IV) at initial diagnosis. From the total number
of patients, 30 (28.3%) had dead and 37 (34.9%) pre-
sented with disease progression during the follow-up for
five years. Detailed clinical information is shown in
Table 1, and detailed clinical and treatment information
for each patient is shown in additional file 1.
The characteristics of the immunochemical variables and
their relationship with NPC clinicopathological features
To characterize the subsets of TIL in NPC tissues, we
defined the different lymphocyte subsets by specific anti-
bodies: CD8 for CTL, Granzyme B (GrB) for activated
CTL, Foxp3 for Tregs and IL-17 for Th17 cells. The
CD8 immunostaining demonstrated cytomembrane
Table 1 Clinical characteristics of 106 patients with NPC
Characteristics No. (%)
Age, years
Median 49
Range 22-73
Gender
Male 84 (79.2)
Female 22 (20.8)
Tumor (T) stage
T1 24 (22.6)
T2 33 (31.1)
T3 33 (31.1)
T4 16 (15.1)
Lymphoid Nodal (N) status
N0 18 (17.0)
N1 46 (43.4)
N2 36 (29.2)
N3 11 (10.4)
Distant metastasis (M) status
M0 101 (95.3)
M1 5 (4.7)
TNM stage
I 6 (5.7)
II 32 (30.2)
III 39 (36.8)
IVa+IVb 29 (27.4)
Progression
No 69 (65.1)
Yes 37 (34.9)
Death
No 76 (71.7)
Yes 30 (28.3)
Histological type*
Type I 1 (0.9)
Type II 13 (12.3)
Type III 92 (86.8)
LMP1
Positive 47 (44.3)
Negative 56 (52.8)
Missing 3(2.8)
* Type I: squamous cell carcinoma; Type II: non-keratinizing carcinoma; Type
III: undifferentiated carcinoma
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Page 2 of 11staining in a subset of TIL around the tumor nests (Fig
1A). The median number of CD8+ cells was 52.50 ±
4.97 cells/high-power field (HPF) and the range was
0.80-231.30 cells/HPF. GrB immunostaining showed a
cytoplasmic pattern (Fig 1B) in a subset of lymphocytes
in tumor tissues. The median number of GrB
+ cells was
32.45 ± 3.01 cells/HPF, and the range was 0.40-160.60
cells/HPF. Foxp3 immunostaining demonstrated nuclear
staining in a subset of lymphocytes around tumor tis-
sues (Fig 1A, B, and 1C). The median number of Foxp3
+ cells was 87.23 ± 5.50 cells/HPF, and the range was
5.20-322.80 cells/HPF. IL-17 immunostaining established
a cytoplasmic pattern (Fig 1C) in a small subset of
lymphocytes around tumor tissues. The median number
of IL-17
+ cells was 5.60 ± 2.36 cells/HPF and the range
was 0.00-150.00 cells/HPF. The CD8/Foxp3 double posi-
tive subset (Fig 1A) showed a median number of 0.9 ±
0.16 cells/HPF and a range of 0.00-9.30 cells/HPF in
TIL. The Foxp3/GrB double positive subset (Fig 1B)
showed a median number of 1.8 ± 0.38 cells/HPF and a
range of 0.01-22.80 cells/HPF in TIL (Table 2). By gen-
eral logical linear regression analysis, no significant cor-
relation was found between the densities of any two
types of lymphocytes in the present study.
To investigate the association between the density of dif-
ferent types of lymphocytes and clinical features in NPC
patients, the median density of each type lymphocyte was
used to separate the patients into high and low TIL
groups. The density of CD8
+ TIL was positively associated
with lymphoid nodal status in NPC patients (P = 0.038)
while the densities of GrB and Foxp3-positive cells were
negatively associated with the T stage (P < 0.01). The den-
sity of GrB
+TIL was negatively associated with the age of
patients (P = 0.011) and the density of Foxp3
+TIL was
negatively associated with NPC clinical stage (TNM stage,
P = 0.043). No correlation was found between the density
of IL-17
+ TIL and the NPC patient clinicopathological
characteristics. No significant association was observed
between any lymphocyte variables and LMP1 expression
in NPC tumor cells (Table 3).
Table 2 Descriptive statistics of immunohistochemical
variables
Variable* Mean SE Median Range
CD8
+ TIL 68.24 4.97 52.50 0.80-231.30
Foxp3
+ TIL 82.21 5.45 74.00 5.20-322.80
Granzyme B
+
TIL
39.98 3.01 32.45 0.40-160.60
IL17
+ TIL 14.75 2.36 5.60 0.00-150.00
CD8
+Foxp3
+
TIL
1.40 0.16 0.90 0.00-9.30
Granzyme B
+
Foxp3
+ TIL
3.10 0.38 1.80 0.00-22.80
Note: *Number of TIL per field (×400).
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Figure 1 Double immunohistochemical staining for CD8/Foxp3, Foxp3/GrB and Foxp3/IL-17. A. NPC tumor tissue with numerous CD8
+
(red) and Foxp3
+ (brown) cells (× 200). B. NPC tumor tissue with numerous Foxp3
+ (brown) and GrB
+ (red) cells (× 200). C. NPC tumor tissue
with numerous Foxp3
+ (red) and IL-17
+ (brown) cells (× 200). The staining patterns show that CD8 is on the cell membrane, GrB and IL-17 are in
the cytoplasm, and Foxp3 is in the nucleus. There are a few CD8
+Foxp3
+ and Foxp3
+GrB
+ cells, but no Foxp3
+IL-17
+ cells.
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subset of co-expression of GrB
+ and Foxp3
+ TIL and
clinicopathological characteristics, however the density
of CD8
+Foxp3
+TIL was positively associated with the
lymphoid nodal status (P = 0.006) and increasing age (P
= 0.041, Table 4). Finally, no co-expression of IL-17 and
Foxp3 was found in NPC TIL by double immunohisto-
chemical staining (data not shown).
Immunohistochemical variables and survival evaluation
Of these 106 NPC patients, Kaplan-Meier and log-rank
test analyses indicated that the groups with Foxp3
+TIL>77.2 cells/HPF (median, n = 53) had a significantly
better overall survival (OS, 65 vs. 56 months, median/5
year, P = 0.01) and progression-free survival (PFS, 64 vs.
52 months, median/5 year, P = 0.002) when compared
to the groups with Foxp3
+TIL = 77.2 cells/HPF (median,
n = 53) (Fig 2). However, the number of CD8
+,G r B
+ or
IL-17
+ TIL is not significantly associated with OS or
PFS (data not shown). Upon univariate analysis, age,
sex, LMP1 expression, and densities of CD8
+TIL, GrB
+TIL and IL-17
+TIL showed no prognostic significance
for OS and PFS. In contrast, tumor size, lymphoid nodal
status, TNM clinical stage and the density of Foxp3
+TIL
were predictors for OS and PFS (Additional File 2).
Furthermore, the multivariate Cox proportional hazards
analysis of covariates displayed P <0 . 0 5i nu n i v a r i a t e
analysis (tumor size, lymphoid nodal status, TNM clini-
cal stage and the number of Foxp3
+TIL) indicating that
after backward elimination, Foxp3 becomes a strong
independent favorable prognostic factor for OS and PFS
(P < 0.01, Table 5).
The multivariate Cox proportional hazards assessment
indicated that the ratio of CD8 to Foxp3 is an indepen-
dent feature in the PFS survival of patients (RH = 2.39,
P = 0.016) and the combination of Foxp3 and GrB is
also an independent prognostic factor in NPC (Table 6).
The high expression of Foxp3 and GrB correlated with
better OS (66 vs. 51 months, median/5 year) and PFS
(64 vs. 46 months, median/5 year) compared to low
expression of Foxp3 and GrB (RH<1, P < 0.01) (Fig 2).
Immunohistochemical variables and survival evaluation in
the patients with different disease stages
To further evaluate the association between different
lymphocyte variables and the patient outcome, we classi-
fied the patients by their clinical stages: early disease
(stages I and II, n = 38) and late disease (stages III and
IV, n = 68). We assessed the correlation between the
density of CD8, GrB, Foxp3 and IL-17 positive TIL and
patient outcome in different disease stages. Our results
showed that, in early disease stage patients, a higher
number of CD8
+TIL was significantly associated with
poor PFS (P = 0.025) without significant association
with OS. A higher ratio of CD8 to Foxp3 was also
found to be significantly associated with poor OS and
PFS (P = 0.041 and 0.001, respectively, Fig 3A). How-
ever, the aforementioned factors did not significantly
Table 3 Association of the CD8
+, Granzyme B
+, Foxp3
+ or IL17
+ TIL number and clinicopathological characteristics in
NPC patients
Characteristics CD8 Positive Granzyme B Positive Foxp3 Positive IL17 Positive
≤52.50
(n = 53)
> 52.50
(n = 53)
P ≤32.45
(n = 53)
> 32.45
(n = 53)
P ≤74.00
(n = 53)
>74.00
(n = 53)
P ≤5.60
(n = 54)
>5.60
(n = 52)
P
Age, years
≤49 27 27 21 34 24 31 27 28
>49 26 25 0.846 32 19 0.011* 29 22 0.174 27 24 0.692
Gender
Male 41 43 41 43 39 44 42 42
Female 12 10 0.632 12 10 0.632 14 8 0.359 12 10 0.704
Tumor (T) stage
T1+T2 28 29 22 35 21 36 26 31
T3+T4 25 24 0.846 31 18 0.011* 32 17 0.003* 28 21 0.236
Lymphoid Nodal (N)
status
N0 13 5 9 9 10 8 9 9
N1-3 40 48 0.038* 44 44 1.000 43 45 0.605 45 43 0.930
TNM Clinical stage
I+II 21 17 16 22 14 24 15 23
III+IVa+IVb 32 36 0.418 37 31 0.224 38 29 0.043* 39 29 0.077
LMP1
- 2 53 1 3 02 6 2 82 8 3 12 5
+ 27 20 0.195 22 25 0.494 23 24 0.914 21 26 0.280
*P < 0.05, as determined by the Pearson chi
2 test.
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shown). In contrast, a higher Foxp3
+TIL number was
significantly associated with a better OS (P = 0.012) and
PFS (P = 0.001) in late stage patients (Fig 3B), but had
no significant influence on OS and PFS in early stage
patients. Additionally, the combination of tumor infil-
trating Foxp3
+ cells and GrB
+ activated CTL was asso-
ciated with the survival of late stage patients: a higher
number of Foxp3
+ and GrB
+ cells was associated with a
longer OS and PFS compared to a lower number of
Foxp3
+ and GrB
+ cells (P < 0.001, Fig 3B).
Discussion
To better understand the special immunological state of
the inflammatory background in NPC and its contribu-
tion to the clinicopathological characteristics and prog-
nosis of NPC patients, we characterized the T cell
infiltrating lymphocytes in a series of cases by immuno-
histochemical staining with antibodies specific to CTL,
activated CTL, Treg and Th17 subsets. We have demon-
strated that the number of Foxp3
+TIL (Treg) was signif-
icantly associated with a favorable outcome (OS and
PFS) in Chinese NPC patients (Fig 2); this association
was correlated with the disease stage since Foxp3 was a
favorable factor for survival in late stage patients but no
significant influence on the early stage patients (Fig 3B,
P < 0.01). Furthermore, multivariate Cox proportional
hazards analysis indicated that Foxp3 was a strong
favorable prognostic factor for OS and PFS for all
patients (HR = 0.233, P < 0.01, Table 5). Our result is in
line with published reports that the Foxp3
+TIL is posi-
tively associated with better survival in EBV-associated
classic Hodgkin lymphoma and follicular lymphoma
[29,30]. Due to their ability to suppress naïve T cells
and effector T cells, Treg cells are usually defined as
immune suppression cells that inhibit antitumor immu-
nity and help tumor cell immune evasion. Some studies
even found that the number of tumor infiltrating Foxp3
+Treg cells was completely associated with poor survival
in several kinds of solid carcinoma such as ovarian and
cervical cancers [15,31-34]. Since it is difficult to define
the general function of Treg cells in all types of cancer,
we suggest that the function of Treg in the tumor
microenvironment should be specifically analyzed in dif-
ferent malignancies. Undifferentiated NPC is associated
with EBV infection. The virus antigens expressed in the
tumor cell are neo-antigens recognized by host immune
cells, so many different lymphocytes are homing to
tumor tissues including CD8+ T cells, CD4+ T cells and
other immune cells. The possible role of Tregs in con-
trolling immune response in the NPC microenviron-
ment to prevent lymph node spreading of the cancer
cell is worthy of recognition. A recent study also
demonstrated that the Foxp3
+ Treg cells could facilitate
early immune responses to local viral infection at least
in part by orchestrating a timely homing of immune
Table 4 The association of the number of CD8
+ Foxp3
+ TIL, Foxp3
+ Granzyme B
+ TIL and the ratio of CD8
+ Foxp3
+ to
CD8+ and GranzymeB
+ Foxp3
+ to Foxp3 TIL and clinicopathological characteristics in NPC patients
Characteristics CD8
+Foxp3
+ Granzyme B
+Foxp3
+
≤0.90
(n = 53)
> 0.90
(n = 53)
P ≤1.80
(n = 54)
> 1.80
(n = 52)
P
Age, years
≤49 24 31 26 29
> 49 29 22 0.174 28 23 0.432
Gender
Male 39 45 42 42
Female 14 8 0.151 12 10 0.704
Tumor (T) stage
T1+T2 25 32 29 28
T3+T4 28 21 0.173 25 24 0.988
Lymphoid Nodal (N)
status
N0 14 4 10 8
N1-3 39 49 0.010* 44 44 0.866
TNM Clinical stage
I + II 18 20 19 19
III+IVa+IVb 35 33 0.685 35 33 0.885
LMP1
- 2 33 3 3 02 6
+ 27 20 0.098 22 25 0.494
Note. *P < 0.05, as determined by the Pearson chi
2 test.
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the ratio of CD8
+TIL to Foxp3
+TIL (CTL/Treg cells)
was significantly associated with poor OS and PFS in
early stage patients (Fig 3A), but had no effect on late
stage patients, implying that increased number of Foxp3
+Treg cell together with decrease number of CD8
+CTL
could suppress tumor growth and lymph node metasta-
sis at the early-stage of NPC (high CD8
+TIL number is
positively associated with N stage in Table 3). There are
three types of Treg including thymic-derived naturally-
occurring Tregs (nTreg), antigen-induced Tregs (iTreg)
and TGFb+ Treg cells (Th3). The mechanisms of sup-
pressing proliferation of naïve or effector T cells of
these Treg cells are controlled by cell-to-cell contact or
secreting cytokines IL-10 and TGFb [36-42]. However, it
has been reported that these Treg cell subpopulations
are unstable in vivo and able to shift to IL-17 secreting
cells[4,43,44]. Moreover, the anti-tumor role of these
subset cells has not been clarified. However, it has been
identified that some tumor derived Treg cells with the
tumor antigen specificity could recognize the autologous
antigen specific tumor cell and secret IFNg in vitro [45].
In the present study, we found that a high density of
Treg (Foxp3
+TIL) was a favorable factor, while the
increased number of CD8
+ CTL was not a favorable fac-
tor in NPC patients. We are currently evaluating the
functions and related mechanism of Foxp3
+Treg cell
Table 5 Multivariate analysis of factors and Foxp3
+ TIL associated with survival
Variables OS (n = 106) PFS (n = 106)
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Tumor (T) stage (4+3/2
+1)
0.803 0.331-1.949 0.627 0.930 0.408-2.119 0.863
Nodal (N) status (3+2
+1/0)
5.181 0.679-40.071 0.115 3.880 0.886-16.994 0.072
TNM stage (III+IVa
+IVb/I+II)
2.582 0.798-8.351 0.113 1.704 0.622-4.674 0.300
Foxp3
+ TILs (high/low) 0.378 0.170-0.841 0.017* 0.331 0.161-0.682 0.003*
NOTE: The Cox proportional hazards regression model was used in univariate analysis.
Figure 2 Results of survival rate with immunohistochemical variables. Individually, the number of Foxp3
+ cells (A and D), the ratio of CD8
+TIL to Foxp3
+ TIL (B and E) and Foxp3 together with GrB
+ cells (C and F) are significantly associated with the overall survival (OS, P < 0.005)
and progression-free survival (PFS, P < 0.005) in NPC patients.
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+ TIL to Foxp3
+ TIL and Foxp3
+ TIL combined with
Granzyme B
+ TIL with survival
Variables OS (n = 106) PFS (n = 106)
Hazard Ratio 95% CI P Hazard Ratio 95% CI P
The ratio of CD8 to
Foxp3
Tumor (T) stage (4+3/2
+1)
1.007 0.419-2.420 0.988 1.185 0.523-2.686 0.685
Nodal (N) status (3+2
+1/0)
4.172 0.545-31.939 0.169 2.821 0.655-12.154 0.164
TNM stage (III+IVa
+IVb/I+II)
2.444 0.754-7.928 0.136 1.561 0.569-4.286 0.387
CD8/Foxp3 (high/low) 1.898 0.885-4.071 0.100 2.393 1.174-4.874 0.016*
Combination of
Foxp3 and GrB
Tumor (T) stage
(4+3/2+1)
0.647 0.256-1.639 0.359 0.750 0.318-1.768 0.510
Nodal (N) status
(3+2+1/0)
5.798 0.757-44.421 0.091 4. 681 1.080-20.280 0.039*
TNM stage (III+IVa
+IVb/I+II)
3.078 0.940-10.075 0.063 2.093 0.759-5.78 0.153
Combination of
Foxp3
+ and
Granzyme B
+ TIL
Overall NA 0.028* NA 0.001*
Foxp3GrB high VS
Foxp3GrB low
0.314 0.111-0.887 0.029* 0.197 0.072-0.540 0.002*
Figure 3 Results of survival rate with immunohistochemical variables in different disease stages (n = 39). A. In the early disease stage,
the number of CD8
+ cells (A and C) and the ratio of CD8
+TIL to Foxp3
+ TIL (B and D) are significantly associated with PFS (P < 0.05). B. In the
late disease stage, the number of Foxp3
+ cells (A and C) and Foxp3
+ together with GrB
+ cells (B and D) are significantly associated with OS (P <
0.01) and PFS (P < 0.01).
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experiment.
The cytotoxic T cell (CTL) has been assigned an
important role in antitumor immunity, but in our
results the CD8
+ CTL density was positively associated
with poor PFS (Fig 3A) in early stage patients, and with
the lymphoid nodal spreading (Table 3). This result was
unexpected; however, we have previously found that the
CD8
+TIL from NPC patients failed to release IFNg by
the stimulation of autologous EBV-specific antigen cells
in vitro [46]. Therefore, a possible explanation for this
result is that a CD8
+ CTL function is impaired thus the
CD8
+ CTL could not kill the tumor cell in NPC TIL.
Another possibility is that the acute immune response
could induce the spreading of tumor cells to the regio-
nal lymphoid node. To further evaluate the function of
tumor infiltrating CTL in NPC, we detected Granzyme
B positive activated CTL in TIL. In our data, the The
number of activated CTL (GrB
+TIL) is negatively asso-
ciated with tumor stage (the same as Treg) and signifi-
cantly decreased in the senior age patient group (P <
0.01, Table 3). However, the higher number of activated
CTL seems to correlate with better OS and PFS in total
NPC patients (P = 0.14 and 0.10, respectively) and in
late disease stage patients (P = 0.19 and 0.08, respec-
tively) although no statistical significance was found
(data not shown). Our further evaluation of the correla-
tion and imbalance of CTL and Treg cell in NPC TIL
showed that the ratio of CD8/Foxp3 was significantly
associated with poorer OS and PFS in early stage
patients (P = 0.04 and 0.001, respectively). When we
evaluated the impact of the combination of Treg and
activated CTL densities, our results showed that the
higher density of Treg and activated CTL was associated
with better survival in total and late stage patients (OS
P = 0.005 and 0.015, respectively; PFS P = 0.001 and
0.003, respectively). One published report in 2002
showed that the number of activated CTL was asso-
ciated with a rapid fatal outcome in 43 NPC patients
[ 4 7 ] ;a n o t h e rp u b l i s h e dr e p o r ti n2 0 0 9s h o w e dt h a tt h e
number of Treg cells was increased while the expression
of the ζ-chain decresed in NPC tumor tissues compared
to normal nasopharynx tissues[48]. Our results seem to
contradict these finding, but the discrapensy may be due
to differences in sample sizes and racial origins.
In order to understand the role of the CD8
+Foxp3
+Treg and GrB
+Foxp3
+ activated Treg cell subsets in
NPC tumor tissues, we double stained CD8 and Foxp3,
and GrB and Foxp3. The CD8
+Foxp3
+ and GrB
+Foxp3
+
TIL were in small number (1.39 ± 0.9 cells/HPF and
3.52 ± 2 cells/HPF, respectively) compared to the total
TIL. We found that the number of CD8 and Foxp3 dou-
ble positive TIL was positively correlated with tumor
lymphoid nodal metastasis in NPC patients (P = 0.006)
( t h es a m ea sC D 8
+TILs). However, no correlation
between GrB
+Foxp3
+TIL and clinicopathological charac-
teristic NPC patients was found (Table 4). Although
many publications have showed that the expression of
Granzyme B is a marker of activated Treg and the activ-
i t yo fT r e gi sd e p e n d e n to nt h eG r a n z y m eBp a t h w a y
[49,50], it remains difficult to define the function of the
GrB
+Foxp3
+ subset in NPC.
In total human CD4
+ T cells, in addition to the tradi-
tional Th1 and Th2 helper T cell subsets, Treg and
Th17 cell populations have also been identified. The
Th17 cell is newly characterized by secretion of IL-17,
IL-22, and IL-21 with or without IFN-g, and its function
is opposite to that of the Treg cell in autoimmune dis-
ease since Th17 cells usually promote inflammatory pro-
cesses [51-54]. The characteristic of Th17 cells in NPC
is unknown. We therefore detected the IL-17
+TIL by
double staining of IL-17 and Foxp3. We could not find
IL-17
+Foxp3
+TIL by IHC staining in vivo, although
there are several recent reports of the in vitro detection
of Il-17 and Foxp3 double positive cells in human
[4,55]. We also found IL-17-secreting T clones highly
expressing Foxp3, and with the suppression function to
naïve T cells from NPC TIL in vitro (unpublished data),
the failure to find the double IL-17 and Foxp3 positive
TIL in NPC may be due to the lack of sensitivity of the
IHC staining method or the differences between in vivo
and in vitro conditions. In our study, no correlation
between the number of IL-17
+TIL and the clinicopatho-
logical characteristics was found (Table 3). We also
could not find a significant association between the
number of IL-17
+TIL and outcome of patients by uni-
variate analysis (See additional file 2) although it seems
that a higher number of IL-17
+TIL was associated with
better OS and PFS of patients (P = 0.19 and 0.39, data
not shown); however, this association was not statisti-
cally significant. Recently, Zou and colleagues also
reported that in ovarian cancer the number of Th17
cells was associated with a better outcome [56].
Conclusions
Our present study found that the tumor infiltrating
Foxp3
+ Treg cell was an independent favorable factor
for the T stage and for survival in the NPC patients,
while the tumor infiltrating CD8
+,G r B
+ or IL-17
+ cells
was not an independent factor for survival. Furthermore,
the ratio of CD8
+TIL to Foxp3
+TIL was significantly
associated with poor OS and PFS in all NPC patients
and poor PFS in the patients with early stage diseases,
and was an independent factor for PFS in multivariate
analyses. Our results support the assumption that the
Treg cell but not the CTL take a favorable role in anti-
tumor immunity of the NPC patients. These could be
explained by the impaired function of CTLs in NPC
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+TIL
and GrB
+TIL (activated CTL) was an independent favor-
able factor and was significantly associated with
improved outcomes of OS and PFS in the patients with
late-stage disease further support the assumption of the
favorable role of Treg in NPC patients. In conclusion,
our study discloses contrasting roles of tumor infiltrat-
ing lymphocyte subsets in the immunomodulation of
NPC, and gives some support for the new strategy
choice of immunotherapy for NPC.
Methods
Tissue specimens
Formalin-fixed, paraffin-embedded tissues from 106
NPC patients were used. The NPC biopsy specimens
were collected between 2002 and 2003 at the Sun Yat-
sen University Cancer Center. Adequate clinical follow-
up data were available in these patients. NPC were clas-
sified histologically into three types according to WHO
classification: squamous cell carcinoma (SCC, type I),
non-keratinizing carcinoma (NKC, type II) and undiffer-
entiated carcinoma (UC, type III). The disease stage of
each patient was classified by the 2002 AJCC staging
system [57]. The characteristics of the NPC patients are
shown in Table 1. This study was conducted in accor-
dance with the Helsinki Declaration, and all patients
signed a consent form approved by the Research Ethics
Committee of the Sun Yat-sen University Cancer
Center.
Immunohistochemistry
The paraffin-embedded tissues were sectioned continu-
ously at a thickness of 4 μm. The co-expression of
F o x P 3w i t hC D 8a n do fG r a n z y m eBw i t hI L - 1 7w e r e
detected by sequential double-immunohistochemical
staining according to the instructions of the double-
staining EnVison™ G/2 Doublestain System (DakoCyto-
mation, Glostrup, Denmark), or using the EnVison™
Detection Kit (DakoCytomation, Glostrup, Denmark) for
LMP1. In brief, the tissue sections were deparaffinized
and then rehydrated through graded alcohols, sections
were immersed into preheated EDTA (PH 8.0). Antigen
retrieval were performed by microwave (95°C for 10
min for LMP1; 95°C for 18 min for other antigens), and
then allowed to cool to room temperature. Endogenous
peroxidase and alkaline phosphatase activities were
blocked with dual endogenous enzyme block reagent
from the doublestain kit, and nonspecific binding sites
were blocked with goat serum at room temperature for
20 min. Primary antibodies including mouse monoclonal
anti-EBV LMP1(Clone CS.1-4, DAKO, Glostrup, Den-
mark; diluted at 1:80), mouse anti-human CD8(Clone
CD8/144B, DAKO, Glostrup, Denmark; diluted at 1:40),
mouse anti-human Granzyme B (clone GrB-7, Glostrup,
Denmark; diluted at 1:25), mouse anti-human Foxp3
(Clone 221D/D3, Santa Cruz Biotechnology, CA, USA,
d i l u t e da t1 : 1 0 0 ) ,a n dg o a tm o n o c l o n a la n t i - h u m a nI L -
17(R&D Systems, Abingdon, UK; diluted at 1:300) were
incubated at 4°C overnight, and developed with peroxi-
dase and 3,3’-diaminobenzidine tetrahydrochloride
(brown), or permanment red (red).
Data were obtained by counting the positively stained
lymphocytes in 5 separate 400× high-power microscopic
fields (HPFs) and calculating the mean number of posi-
tively stained cells per HPF. Mouse IgG1 (DAKO) and
normal goat IgG (Santa) negative control stains were
generated and evaluated.
Statistical Analysis
All data analysis was carried out with the SPSS 13.0
software (SPSS, Chicago, IL, USA). The median value
was used to cut off the subgroups of all immunohisto-
chemical variables in our data. The Pearson chi
2 test
was carried out to assess the relationship among lym-
phocytic variables and clinicopathological characteristics.
Two-tailed P < 0.05 was judged to be significant.
Overall survival (OS) was defined as the period from
initial diagnosis to death by any cause; progression-free
survival was defined as time from initial diagnosis to the
progression of NPC or death by any cause. Cumulative
survival time was calculated by the Kaplan-Meier
method and analyzed by the log-rank test. Univariate
and multivariate analyses were based on the Cox pro-
portional hazards regression model.
Additional file 1: The record of experiment and clinical data for
each NPC patient. All results for Description: immunochemical variables
and clinical information, fellow-up data for each patient were shown in
this excel file.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-4-
S1.XLS]
Additional file 2: Univariate analyses of factors associated with
survival of patients. The Description: univarate statistic analyses for the
association of age, gender, TNM stage and immunochemical variables
including LMP1, CD8, GrB, Foxp3 and IL-17 and the survival of patients.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-4-
S2.DOC]
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